EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-MG-03(Investigational Cellular Protocol)
Clinical Overview & Biological Mechanism
Pathology, cellular action of Mesenchymal Stem Cells (MSCs), and investigational intent
The Pathology:
Myasthenia Gravis (MG) is an autoimmune disorder where autoantibodies (targeting AChR, MuSK, or LRP4 receptors) destroy postsynaptic acetylcholine receptors at the neuromuscular junction, leading to rapid muscle fatigue.
The Cellular Mechanism:
Umbilical cord-derived Mesenchymal Stem Cells (UC-MSCs) act as paracrine and immunomodulatory agents. Preclinical studies indicate they secrete soluble factors (PGE2, TGF-β, IDO) that:
- Inhibit overactive T-follicular helper (Tfh) and Th17 inflammatory subsets.
- Upregulate forkhead box P3 (FoxP3+) regulatory T cells (Tregs).
- Dampen systemic inflammatory cascades without producing non-specific bone marrow ablation.
Investigational Intent:
This is an adjunctive, non-curative cellular intervention designed to assist in re-establishing immune balance, reducing autoantibody burden, and stabilizing clinical status in therapy-refractory patients.
Candidate Screening & Safety Triage
Inclusion criteria, absolute safety exclusions, and pre-arrival diagnostic clearance
Eligible Profiles for Assessment:
- Adults (18–70 years) with clinically and serologically verified Generalized or Ocular MG (AChR-Ab+, MuSK-Ab+, or EMG-confirmed seronegative).
- Baseline forced vital capacity (FVC) > 70% of predicted value, clinically stable for international travel.
- Active or impending Myasthenic Crisis (FVC < 15–20 mL/kg, signs of acute respiratory insufficiency or severe bulbar failure). Requires emergency critical care ICU admission, not elective outpatient cell therapy.
- Active malignancy, unmanaged thymoma, severe systemic infection, or severe uncorrected coagulopathies.
Potential Improvements & Realistic Clinical Boundaries
Reported functional goals alongside documented non-responder rates and realistic limits
- Every immune profile is unique. Outcomes vary widely; stem cell therapy is not a definitive cure and is strictly adjunctive to established medical therapies.
Clinical Safety Profile & Anticipated Adverse Reactions
Anticipated transient reactions, procedural safeguards, and long-term surveillance
- While non-manipulated allogeneic UC-MSCs have an established general safety profile, patients may experience mild, transient adverse events:
Rare Risks:
Allergic hypersensitivity reactions (monitored continuously during infusion with bedside emergency medication).
Step-by-Step Treatment Schedule & In-Hospital Workflow
Structured clinical itinerary during your stay in India (4 to 6 Days)
Day 1–2 (Baseline Hospital Evaluation):
- Face-to-face evaluation by board-certified neurologist.
- Day 3–6 (Cellular Infusion & Supportive Therapies):
- Certified, cryopreserved, or freshly formulated UC-MSCs infused intravenously under sterile conditions.
- Integrated daily neuro-physiotherapy, energy-conservation training, and respiratory diaphragmatic coaching.
- Day 7–8 (Clinical Post-Assessment & Discharge):
- Exit assessment, neurological stability check, delivery of treatment summary reports.
Why Receive Care at Our Specialized Center in India?
Super-specialist clinical oversight, cGMP cleanroom facilities, and high cell viability
Transparent Pricing Scope:
Fixed packages range from $5,800 to $7,500 USD. Includes cell processing, infusions, hospital daycare fees, physician consultations, and baseline routine labs. Excludes travel, lodging, third-party ICU admissions for unrelated complications, and home medications.
Treatment Costs & Comparative Package Inclusions
Transparent international pricing with comprehensive hospital, cellular, and logistical inclusions
(Comprehensive package covering targeted UC-MSCs, procedural suites, specialist fees, and 12-month monitoring).
(Administered under strict ISO Class 5 cleanroom standards and institutional ethics oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Specialized Centers) | $5,200 – $7,800 USD | 1 – 2 Weeks | NABH / JCI Accredited |
| United States | $35,000 – $65,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $28,000 – $55,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $32,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
Full medical concierge care, government visa assistance, and airport transit
Medical Visa (MED) Processing:
Official Indian Embassy/FRRO Visa Invitation Letters issued within 24–48 hours of medical approval.
Dedicated Case Management:
A bilingual international liaison assists with appointments, medical records translation, and on-ground logistics.
Airport & Ground Transit:
Private wheelchair-capable airport pick-up/drop-off and transfers between hotel and clinic.
Language & Dietary Support:
Translators available for Arabic, Russian, and French; dietary arrangements available (Halal, Vegetarian, Continental).
Logistics & Accessible Accommodation
Daycare outpatient protocol, nearby wheelchair-accessible partner lodging, and daily transfers
Daycare Model:
Patients undergo monitoring and treatment during morning sessions, returning to private accommodations by afternoon.
Regulatory Disclosures & Ethical Declarations
Statutory compliance under ICMR-DBT National Guidelines and vital medication advisories
Peer-Reviewed Clinical Literature & Scientific Context
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Scientific Notice on Study Types:
Scientific Notice on Study Types: References 1–3 examine Autologous Hematopoietic Stem Cell Transplantation (AHSCT), a high-intensity bone-marrow transplant protocol utilizing chemotherapy conditioning in specialized inpatient hematology units. Reference 4 evaluates the biological mechanism of Mesenchymal Stem Cells (MSCs), the cell type utilized in our investigational daycare program. They are provided below to support informed decision-making and discussions with your primary neurologist.
Bryant et al. (JAMA Neurology, 2016)
Bryant A, et al. Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation. JAMA Neurol. 2016;73(6):652–658. PubMed ID: PMID: 27043206
Schlatter et al. (Ann Clin Transl Neurol, 2023)
Schlatter MI, et al. Remission of severe myasthenia gravis after autologous stem cell transplantation. Ann Clin Transl Neurol. 2023;10(11):2105–2113. Registry / ID: ClinicalTrials.gov: NCT00716066 | PMCID: PMC10646993
Beland et al. (Muscle & Nerve, 2023)
Beland B, et al. Autologous hematopoietic stem cell transplant for the treatment of refractory myasthenia gravis with anti-muscle specific kinase antibodies. Muscle Nerve. 2023;67(2):154–157. PubMed ID: PMID: 36472093
Sudres et al. (JCI Insight, 2017) — Mesenchymal Stem Cell Model
Sudres M, et al. Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model. JCI Insight. 2017;2(7):e89665. PubMed ID: PMID: 28381534 | PMCID: PMC5374074
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Myasthenia Gravis (MG)